Global pharmaceutical company AstraZeneca has partnered with Ghanaian precision medicine company Revna Biosciences to enhance access to advanced lung cancer testing and targeted therapies.
The collaboration focuses on improving diagnosis and treatment for non-small cell lung cancer (NSCLC), the most common form of lung cancer, through Epidermal Growth Factor Receptor (EGFR) biomarker testing. This cutting-edge approach allows doctors to identify specific genetic mutations in a patient’s cancer cells and prescribe personalized treatments that are often more effective than traditional chemotherapy.
The first step in the collaboration is to map and streamline the patient journey, from accurate diagnosis through treatment, to improve health outcomes. Beyond providing advanced biomarker testing resources, this partnership will offer educational programs and workshops to equip healthcare professionals in the lung cancer space with next-generation tools, aiming for earlier detection and better clinical outcomes, ultimately contributing to global cancer control.
Dr. Derrick Edem Akpalu, CEO and Co-Founder of Revna Biosciences, also spoke about the importance of the partnership “This collaboration is timely, as the demand for personalized healthcare is growing. Advances in EGFR testing and targeted therapies hold unprecedented promise for enhanced cancer care in Ghana. Together, we aim to raise awareness and increase access to life-saving treatments, ensuring that every patient in Ghana has the best chance to thrive. The knowledge we gain today will help shape a better tomorrow for patients here and around the world.”
Dr. Khomotso Mashilane, Medical Director African Cluster at AstraZeneca remarked on the program’s potential impact: “At AstraZeneca, we are committed to working collaboratively with governments, healthcare professionals, and patient communities to create resilient healthcare systems and expand access to innovative cancer treatments for patients across Africa. By investing in EGFR biomarker testing and precision medicine, we are taking a pivotal step toward giving patients in Ghana the treatments they need and deserve.
